Group 1 - The core point of the article is the announcement of the 2025 National Medical Insurance Drug List, which includes a record number of new drugs, emphasizing the focus on genuine innovation in the pharmaceutical sector [1][2] - The 2025 version of the drug list adds 111 new drugs, with 50 classified as first-class new drugs, marking the highest number and proportion in history [1] - The adjustments to the drug list reflect a stricter evaluation process, where drugs that do not meet certain criteria, such as "4 unchanges" drugs and those with exorbitant pricing, are unlikely to pass expert review [1][2] Group 2 - The new drug list includes 114 drugs, with 105 added through negotiations, 7 through competitive bidding, and 2 directly from national procurement, while 29 drugs have been removed due to clinical replacements or long-term supply issues [1] - As of October 2025, the cumulative payment from the medical insurance fund for negotiated drugs exceeds 460 billion yuan, benefiting over 1 billion patients and driving related sales over 670 billion yuan [2] - The evaluation criteria for new drugs emphasize the need for significant clinical value, with a focus on preventing the inclusion of drugs that are expensive or easily abused [2]
中新健康丨“换汤不换药”不是真创新 “4不改”药品难进医保目录
Zhong Guo Xin Wen Wang·2025-12-09 17:23